Cleveland Clinic: Ketamine Shows Promise to Treat Suicidal Depression
Scientists at The Cleveland Clinic are testing whether ketamine, currently used only as an anesthetic, could offer new hope for patients with severe suicidal depression. The groundbreaking study compares this unconventional treatment directly against electroconvulsive therapy, the current gold standard for life threatening depression.
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key Takeaways |
|---|
| Study Focus: Comparing intravenous ketamine vs. electroconvulsive therapy for suicidal depression |
| Current Status: Ketamine only FDA approved as anesthetic, not for depression |
| Timeline: Research discovered ketamine’s antidepressant properties 25 years ago |
| Study Progress: Ongoing at multiple US sites, results expected in several years |
| Target Population: Patients with treatment resistant depression and suicidal thoughts |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
America Faces a Suicide Crisis
The statistics paint a stark picture of mental health in America. Someone dies by suicide every 11 minutes, according to the CDC. In 2023 alone, nearly 13 million adults seriously considered ending their lives. Of those, 1.5 million actually attempted suicide.
Dr. Brian Barnett, who serves as co principal investigator of the Cleveland Clinic study site, believes many of these deaths could be prevented with better treatment options.
Beyond Traditional Treatments
Mental health professionals typically rely on three main approaches for severe depression. Psychotherapy and prescription medications form the foundation of care. When these prove insufficient, doctors turn to electroconvulsive therapy.
ECT remains the most effective treatment for depression and suicidal ideation, despite its intimidating reputation. The procedure uses electrical currents to trigger controlled seizures in the brain, often providing rapid relief for severely depressed patients.
Ketamine Emerges as Unexpected Solution
The ketamine research began 25 years ago when scientists made a surprising discovery. The anesthetic drug showed remarkable ability to treat both treatment resistant depression and suicidal thoughts. This finding opened entirely new pathways for understanding how depression affects the brain.
The current study directly compares intravenous ketamine against ECT. Researchers want to determine whether ketamine delivers comparable results without the more intensive procedures associated with electroconvulsive therapy.
Multiple research sites across the United States are participating in this comprehensive study. Results will not be available for several years, but the research represents a significant step toward expanding treatment options for the most vulnerable patients.
